Amgen Surges to 88th in Trading Volume with $1.722 Billion Day

On April 9, 2025, Amgen's trading volume reached $1.722 billion, marking a 47.61% increase from the previous day. This surge placed Amgen at the 88th position in terms of trading volume for the day. Amgen's stock price rose by 3.86%.

Amgen's recent stock performance can be attributed to several key developments. The company's Uplizna received FDA approval as the first treatment for Immunoglobulin G4-related disease, a condition affecting approximately 20,000 people in the United States. This approval has bolstered investor confidence and contributed to the stock's upward trajectory.

Additionally, Amgen's strong presence in various therapeutic areas, including oncology/hematology, cardiovascular disease, and neuroscience, has solidified its position as a leading biotech company. The successful launch of drugs like Epogen and Neupogen has further enhanced its market standing and investor trust.

Analysts have also played a role in Amgen's recent stock performance. Morgan Stanley analyst Terence Flynn raised the firm's price target on Amgen to $330 from $328, maintaining an Equal Weight rating on the shares. This positive outlook from analysts has likely influenced investor sentiment and contributed to the stock's rise.